On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

Gainers: EKSO +22%. NDRM +13%. AEMD +9%. ALXN +8%. CRVS +7%.Losers: ATNM -17%. VKTX -11%. APTO -10%. ALDX -10%. RGLS -9%.Now read: Alexion: Suspicions Of Improper ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

At the close in NYSE,... Viking Therapeutics (NASDAQ:VKTX) has filed a prospectus for a $450M mixed shelf offering.Now read: Rounds Report: Aveo Catches A Big Payday With NHSScotland Approval Of ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...